Sodium selenate or other selenium derivatives such as selenomethionine, treatment was found to increase expression of the serine/threonine protein phosphatase 2A (PP2A) in cells and mitigate Tau pathology in rodent models of tauopathies, traumatic brain injury (TBI), Alzheimer’s disease (AD), in addition to rescuing behavioral phenotypes and synaptic plasticity in these models [5,6,7,8,9,10,11,12,13]. This evidence concerns the gene PTPA and Alzheimer disease.